Speakers

Expand/Collapse

Rakesh Dixit
Chief Executive Officer & Founder
BioNavigen

Bill Mallet
Staff Scientist
Target Validation Bolt Bio

Day One

Tuesday December 7, 2021

2:00 pm | Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug

10:30 am | Immune-Stimulating Antibody Conjugates Targeting CEA & PD-L1 for Cancer Therapy

Earl Albone
Senior Director of Biochemistry & Bioanalytical Development
Eisai, Inc

Day Two

Wednesday December 8, 2021

2:30 pm | Session Reserved for Eisai

Elaine Hurt
Director, Bioscience
AstraZeneca

Greg Adams
Chief Scientific Officer
Elucida Oncology, Inc

Day Two

Wednesday December 8, 2021

10:30 am | Development & Clinical Translation of ELU001, a Targeted Ultra- Small Topoisomerase 1 C’Dot Conjugate for the Treatment of Solid Tumors

Hans Peter Gerber
Chief Scientific Officer
3T Bioscionces

Day One

Tuesday December 7, 2021

2:00 pm | Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug

Day Two

Wednesday December 8, 2021

10:00 am | Identification of Novel pHLA Targets for Solid Tumor Targeting with ADCs

Jack Elands
Chief Executive Officer
Emergence Therapeutics

Jagath Reddy Junutula
Founder
Aarkus Therapeutics

Day One

Tuesday December 7, 2021

3:30 pm | Chair’s Closing Remarks

10:20 am | Chair’s Opening Remarks

Day Two

Wednesday December 8, 2021

3:00 pm | Chair’s Closing Remarks

10:00 am | Chair's Opening Remarks

John Lambert
Independent Consultant

Lenka Sadilkova
Director of Pharmacology
SOTIO

Day Two

Wednesday December 8, 2021

12:00 pm | SOT102, A Novel CLDN18.2-Targeting Antibody-Drug Conjugate With Strong Therapeutic Potential in Solid Tumors

Martha R. Neagu
Medical Director, Oncology Early Development
AbbVie

Day One

Tuesday December 7, 2021

12:00 pm | Targeting EGFR Through ADCs

Regina Reilly
Oncology Discovery, Biologics & Research Fellow
AbbVie

Day Two

Wednesday December 8, 2021

2:00 pm | Target Identification at the Intersection of Indication & Payload

Robert Lawrence
Senior Scientist
Seagen

Day One

Tuesday December 7, 2021

2:00 pm | Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug

Day Two

Wednesday December 8, 2021

12:30 pm | Quantitative Proteomics Approaches for ADC Target Characterization

Seema Kantak
Vice President
Exelixis

Day One

Tuesday December 7, 2021

2:30 pm | Target Expression & Warhead: The Driving Forces of ADC Activity

Terry Rabbits
Molecular Immunologist
ICR

Day One

Tuesday December 7, 2021

12:30 pm | Targeting Leukaemias with Anti-CD7 Antibody & ADC

Tracy Kuo
Senior Director - Biology & Translational Science
Tallac Therapeutics

Day One

Tuesday December 7, 2021

3:00 pm | Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induces Potent Anti- Tumor Immunity